As a result, NiPT induces apoptosis in CML cells that are resistant to imatinib, doing so through both Bcr/Abl-independent and Bcr/Abl-dependent mechanisms. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.